KAKKIS EMIL D 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO
Transactions
- Award
Common Stock
[F1]2026-03-01+71,177→ 712,908 total - Sale
Common Stock
[F2][F3][F4][F5]2026-03-02$22.80/sh−54,404$1,240,411→ 658,994 total
Holdings
- 2,158,985(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.
- [F2]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
- [F4]Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Signature
/s/ Karah Parschauer, attorney-in-fact|2026-03-03